↓ Skip to main content

Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma

Overview of attention for article published in Cancer Cell, May 2017
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (94th percentile)
  • Good Attention Score compared to outputs of the same age and source (69th percentile)

Mentioned by

blogs
1 blog
twitter
72 X users
patent
2 patents
facebook
2 Facebook pages
f1000
1 research highlight platform

Citations

dimensions_citation
392 Dimensions

Readers on

mendeley
224 Mendeley
citeulike
1 CiteULike
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma
Published in
Cancer Cell, May 2017
DOI 10.1016/j.ccell.2017.04.012
Pubmed ID
Authors

Michail S. Lionakis, Kieron Dunleavy, Mark Roschewski, Brigitte C. Widemann, John A. Butman, Roland Schmitz, Yandan Yang, Diane E. Cole, Christopher Melani, Christine S. Higham, Jigar V. Desai, Michele Ceribelli, Lu Chen, Craig J. Thomas, Richard F. Little, Juan Gea-Banacloche, Sucharita Bhaumik, Maryalice Stetler-Stevenson, Stefania Pittaluga, Elaine S. Jaffe, John Heiss, Nicole Lucas, Seth M. Steinberg, Louis M. Staudt, Wyndham H. Wilson

Abstract

Primary CNS lymphoma (PCNSL) harbors mutations that reinforce B cell receptor (BCR) signaling. Ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, targets BCR signaling and is particularly active in lymphomas with mutations altering the BCR subunit CD79B and MYD88. We performed a proof-of-concept phase Ib study of ibrutinib monotherapy followed by ibrutinib plus chemotherapy (DA-TEDDi-R). In 18 PCNSL patients, 94% showed tumor reductions with ibrutinib alone, including patients having PCNSL with CD79B and/or MYD88 mutations, and 86% of evaluable patients achieved complete remission with DA-TEDDi-R. Increased aspergillosis was observed with ibrutinib monotherapy and DA-TEDDi-R. Aspergillosis was linked to BTK-dependent fungal immunity in a murine model. PCNSL is highly dependent on BCR signaling, and ibrutinib appears to enhance the efficacy of chemotherapy.

X Demographics

X Demographics

The data shown below were collected from the profiles of 72 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 224 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Unknown 223 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 39 17%
Other 28 13%
Student > Bachelor 17 8%
Student > Ph. D. Student 16 7%
Professor 14 6%
Other 52 23%
Unknown 58 26%
Readers by discipline Count As %
Medicine and Dentistry 94 42%
Biochemistry, Genetics and Molecular Biology 18 8%
Immunology and Microbiology 15 7%
Agricultural and Biological Sciences 8 4%
Neuroscience 5 2%
Other 19 8%
Unknown 65 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 48. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 January 2023.
All research outputs
#869,538
of 25,402,528 outputs
Outputs from Cancer Cell
#667
of 3,153 outputs
Outputs of similar age
#17,655
of 327,111 outputs
Outputs of similar age from Cancer Cell
#12
of 36 outputs
Altmetric has tracked 25,402,528 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,153 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 37.3. This one has done well, scoring higher than 78% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,111 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 69% of its contemporaries.